#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Geriatric syndrome refers to a series of symptoms and observations caused by a variety of factors associated with aging , where the older adults show the treatment consciously or otherwise , and long-term care becomes important at the same time .
1-1	0-9	Geriatric	abstract[1]	new[1]	coref	2-4[12_1]
1-2	10-18	syndrome	abstract[1]	new[1]	_	_
1-3	19-25	refers	_	_	_	_
1-4	26-28	to	_	_	_	_
1-5	29-30	a	abstract[2]	new[2]	_	_
1-6	31-37	series	abstract[2]	new[2]	_	_
1-7	38-40	of	abstract[2]	new[2]	_	_
1-8	41-49	symptoms	abstract[2]|abstract	new[2]|new	coref	3-5[26_0]
1-9	50-53	and	abstract[2]	new[2]	_	_
1-10	54-66	observations	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-11	67-73	caused	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-12	74-76	by	abstract[2]|abstract[4]	new[2]|new[4]	_	_
1-13	77-78	a	abstract[2]|abstract[4]|abstract[5]	new[2]|new[4]|new[5]	_	_
1-14	79-86	variety	abstract[2]|abstract[4]|abstract[5]	new[2]|new[4]|new[5]	_	_
1-15	87-89	of	abstract[2]|abstract[4]|abstract[5]	new[2]|new[4]|new[5]	_	_
1-16	90-97	factors	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	coref	16-40[128_6]
1-17	98-108	associated	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-18	109-113	with	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-19	114-119	aging	abstract[2]|abstract[4]|abstract[5]|abstract[6]|abstract	new[2]|new[4]|new[5]|new[6]|new	coref	6-14
1-20	120-121	,	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-21	122-127	where	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-22	128-131	the	abstract[2]|abstract[4]|abstract[5]|abstract[6]|person[8]	new[2]|new[4]|new[5]|new[6]|new[8]	coref	12-10[79_8]
1-23	132-137	older	abstract[2]|abstract[4]|abstract[5]|abstract[6]|person[8]	new[2]|new[4]|new[5]|new[6]|new[8]	_	_
1-24	138-144	adults	abstract[2]|abstract[4]|abstract[5]|abstract[6]|person[8]	new[2]|new[4]|new[5]|new[6]|new[8]	_	_
1-25	145-149	show	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-26	150-153	the	abstract[2]|abstract[4]|abstract[5]|abstract[6]|abstract[9]	new[2]|new[4]|new[5]|new[6]|new[9]	coref	4-13[37_9]
1-27	154-163	treatment	abstract[2]|abstract[4]|abstract[5]|abstract[6]|abstract[9]	new[2]|new[4]|new[5]|new[6]|new[9]	_	_
1-28	164-175	consciously	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-29	176-178	or	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-30	179-188	otherwise	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-31	189-190	,	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-32	191-194	and	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-33	195-204	long-term	abstract[2]|abstract[4]|abstract[5]|abstract[6]|abstract[10]	new[2]|new[4]|new[5]|new[6]|new[10]	coref	3-17[27_10]
1-34	205-209	care	abstract[2]|abstract[4]|abstract[5]|abstract[6]|abstract[10]	new[2]|new[4]|new[5]|new[6]|new[10]	_	_
1-35	210-217	becomes	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-36	218-227	important	abstract[2]|abstract[4]|abstract[5]|abstract[6]	new[2]|new[4]|new[5]|new[6]	_	_
1-37	228-230	at	_	_	_	_
1-38	231-234	the	time[11]	new[11]	_	_
1-39	235-239	same	time[11]	new[11]	_	_
1-40	240-244	time	time[11]	new[11]	_	_
1-41	245-246	.	_	_	_	_

#Text=With respect to geriatric syndrome , often the viewpoint involves the purpose of sustaining the capability for activities of daily living ( ADL ) and improving the quality of life ( QOL ) , rather than just considering the disease condition according to the diagnostic name .
2-1	247-251	With	_	_	_	_
2-2	252-259	respect	_	_	_	_
2-3	260-262	to	_	_	_	_
2-4	263-272	geriatric	abstract[12]	giv[12]	coref	3-5[25_12]
2-5	273-281	syndrome	abstract[12]	giv[12]	_	_
2-6	282-283	,	_	_	_	_
2-7	284-289	often	_	_	_	_
2-8	290-293	the	abstract[13]	new[13]	_	_
2-9	294-303	viewpoint	abstract[13]	new[13]	_	_
2-10	304-312	involves	_	_	_	_
2-11	313-316	the	abstract[14]	new[14]	_	_
2-12	317-324	purpose	abstract[14]	new[14]	_	_
2-13	325-327	of	abstract[14]	new[14]	_	_
2-14	328-338	sustaining	abstract[14]	new[14]	_	_
2-15	339-342	the	abstract[14]|abstract[15]	new[14]|new[15]	_	_
2-16	343-353	capability	abstract[14]|abstract[15]	new[14]|new[15]	_	_
2-17	354-357	for	abstract[14]|abstract[15]	new[14]|new[15]	_	_
2-18	358-368	activities	abstract[14]|abstract[15]|event[16]	new[14]|new[15]|new[16]	coref	7-14[56_16]
2-19	369-371	of	abstract[14]|abstract[15]|event[16]	new[14]|new[15]|new[16]	_	_
2-20	372-377	daily	abstract[14]|abstract[15]|event[16]|abstract[17]	new[14]|new[15]|new[16]|new[17]	coref	7-16[57_17]
2-21	378-384	living	abstract[14]|abstract[15]|event[16]|abstract[17]	new[14]|new[15]|new[16]|new[17]	_	_
2-22	385-386	(	abstract[14]	new[14]	_	_
2-23	387-390	ADL	abstract[14]|abstract	new[14]|new	_	_
2-24	391-392	)	abstract[14]	new[14]	_	_
2-25	393-396	and	abstract[14]	new[14]	_	_
2-26	397-406	improving	abstract[14]	new[14]	_	_
2-27	407-410	the	abstract[14]|abstract[19]	new[14]|new[19]	appos	2-32[0_19]
2-28	411-418	quality	abstract[14]|abstract[19]	new[14]|new[19]	_	_
2-29	419-421	of	abstract[14]|abstract[19]	new[14]|new[19]	_	_
2-30	422-426	life	abstract[14]|abstract[19]|abstract	new[14]|new[19]|new	_	_
2-31	427-428	(	abstract[14]	new[14]	_	_
2-32	429-432	QOL	abstract[14]|abstract	new[14]|giv	_	_
2-33	433-434	)	abstract[14]	new[14]	_	_
2-34	435-436	,	abstract[14]	new[14]	_	_
2-35	437-443	rather	abstract[14]	new[14]	_	_
2-36	444-448	than	abstract[14]	new[14]	_	_
2-37	449-453	just	abstract[14]	new[14]	_	_
2-38	454-465	considering	abstract[14]	new[14]	_	_
2-39	466-469	the	abstract[14]|abstract[23]	new[14]|new[23]	_	_
2-40	470-477	disease	abstract[14]|abstract|abstract[23]	new[14]|new|new[23]	coref	16-45
2-41	478-487	condition	abstract[14]|abstract[23]	new[14]|new[23]	_	_
2-42	488-497	according	_	_	_	_
2-43	498-500	to	_	_	_	_
2-44	501-504	the	abstract[24]	new[24]	_	_
2-45	505-515	diagnostic	abstract[24]	new[24]	_	_
2-46	516-520	name	abstract[24]	new[24]	_	_
2-47	521-522	.	_	_	_	_

#Text=Notably , there are geriatric syndrome symptoms that are more frequent and are largely affected by long-term care , such as , disorders associated with mobility ( remain secluded , or bedridden ) , falls , incontinence , and cognitive impairment .
3-1	523-530	Notably	_	_	_	_
3-2	531-532	,	_	_	_	_
3-3	533-538	there	_	_	_	_
3-4	539-542	are	_	_	_	_
3-5	543-552	geriatric	abstract[25]|abstract[26]	giv[25]|giv[26]	_	_
3-6	553-561	syndrome	abstract[25]|abstract[26]	giv[25]|giv[26]	_	_
3-7	562-570	symptoms	abstract[26]	giv[26]	_	_
3-8	571-575	that	abstract[26]	giv[26]	_	_
3-9	576-579	are	abstract[26]	giv[26]	_	_
3-10	580-584	more	abstract[26]	giv[26]	_	_
3-11	585-593	frequent	abstract[26]	giv[26]	_	_
3-12	594-597	and	abstract[26]	giv[26]	_	_
3-13	598-601	are	abstract[26]	giv[26]	_	_
3-14	602-609	largely	abstract[26]	giv[26]	_	_
3-15	610-618	affected	abstract[26]	giv[26]	_	_
3-16	619-621	by	abstract[26]	giv[26]	_	_
3-17	622-631	long-term	abstract[26]|abstract[27]	giv[26]|giv[27]	coref	5-20[44_27]
3-18	632-636	care	abstract[26]|abstract[27]	giv[26]|giv[27]	_	_
3-19	637-638	,	abstract[26]	giv[26]	_	_
3-20	639-643	such	abstract[26]	giv[26]	_	_
3-21	644-646	as	abstract[26]	giv[26]	_	_
3-22	647-648	,	abstract[26]	giv[26]	_	_
3-23	649-658	disorders	abstract[26]|abstract[28]|abstract[29]	giv[26]|new[28]|new[29]	ana|coref	4-1[0_29]|12-34[86_28]
3-24	659-669	associated	abstract[26]|abstract[28]|abstract[29]	giv[26]|new[28]|new[29]	_	_
3-25	670-674	with	abstract[26]|abstract[28]|abstract[29]	giv[26]|new[28]|new[29]	_	_
3-26	675-683	mobility	abstract[26]|abstract[28]|abstract[29]|abstract	giv[26]|new[28]|new[29]|new	_	_
3-27	684-685	(	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-28	686-692	remain	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-29	693-701	secluded	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-30	702-703	,	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-31	704-706	or	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-32	707-716	bedridden	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-33	717-718	)	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-34	719-720	,	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-35	721-726	falls	abstract[26]|abstract[29]|event	giv[26]|new[29]|new	_	_
3-36	727-728	,	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-37	729-741	incontinence	abstract[26]|abstract[29]|event	giv[26]|new[29]|new	_	_
3-38	742-743	,	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-39	744-747	and	abstract[26]|abstract[29]	giv[26]|new[29]	_	_
3-40	748-757	cognitive	abstract[26]|abstract[29]|abstract[33]	giv[26]|new[29]|new[33]	coref	8-29[69_33]
3-41	758-768	impairment	abstract[26]|abstract[29]|abstract[33]	giv[26]|new[29]|new[33]	_	_
3-42	769-770	.	_	_	_	_

#Text=These are considered issues for which early measures should be incorporated into geriatric treatment .
4-1	771-776	These	abstract	giv	_	_
4-2	777-780	are	_	_	_	_
4-3	781-791	considered	abstract[35]	new[35]	_	_
4-4	792-798	issues	abstract[35]	new[35]	_	_
4-5	799-802	for	abstract[35]	new[35]	_	_
4-6	803-808	which	abstract[35]	new[35]	_	_
4-7	809-814	early	abstract[35]|abstract[36]	new[35]|new[36]	coref	5-5[39_36]
4-8	815-823	measures	abstract[35]|abstract[36]	new[35]|new[36]	_	_
4-9	824-830	should	abstract[35]	new[35]	_	_
4-10	831-833	be	abstract[35]	new[35]	_	_
4-11	834-846	incorporated	abstract[35]	new[35]	_	_
4-12	847-851	into	abstract[35]	new[35]	_	_
4-13	852-861	geriatric	abstract[35]|abstract[37]	new[35]|giv[37]	coref	18-15[0_37]
4-14	862-871	treatment	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
4-15	872-873	.	_	_	_	_

#Text=In recent years , measures against frailty and sarcopenia , which elevate the risk of increasing the need for long-term care , are being considered important .
5-1	874-876	In	_	_	_	_
5-2	877-883	recent	time[38]	new[38]	_	_
5-3	884-889	years	time[38]	new[38]	_	_
5-4	890-891	,	_	_	_	_
5-5	892-900	measures	abstract[39]	giv[39]	coref	13-24[96_39]
5-6	901-908	against	abstract[39]	giv[39]	_	_
5-7	909-916	frailty	abstract[39]|abstract	giv[39]|new	coref	6-1
5-8	917-920	and	abstract[39]	giv[39]	_	_
5-9	921-931	sarcopenia	abstract[39]|abstract[41]	giv[39]|new[41]	coref	14-2[0_41]
5-10	932-933	,	abstract[39]|abstract[41]	giv[39]|new[41]	_	_
5-11	934-939	which	abstract[39]|abstract[41]	giv[39]|new[41]	_	_
5-12	940-947	elevate	abstract[39]|abstract[41]	giv[39]|new[41]	_	_
5-13	948-951	the	abstract[39]|abstract[41]|abstract[42]	giv[39]|new[41]|new[42]	coref	7-7[54_42]
5-14	952-956	risk	abstract[39]|abstract[41]|abstract[42]	giv[39]|new[41]|new[42]	_	_
5-15	957-959	of	abstract[39]|abstract[41]|abstract[42]	giv[39]|new[41]|new[42]	_	_
5-16	960-970	increasing	abstract[39]|abstract[41]|abstract[42]	giv[39]|new[41]|new[42]	_	_
5-17	971-974	the	abstract[39]|abstract[41]|abstract[42]|abstract[43]	giv[39]|new[41]|new[42]|new[43]	coref	7-21[59_43]
5-18	975-979	need	abstract[39]|abstract[41]|abstract[42]|abstract[43]	giv[39]|new[41]|new[42]|new[43]	_	_
5-19	980-983	for	abstract[39]|abstract[41]|abstract[42]|abstract[43]	giv[39]|new[41]|new[42]|new[43]	_	_
5-20	984-993	long-term	abstract[39]|abstract[41]|abstract[42]|abstract[43]|abstract[44]	giv[39]|new[41]|new[42]|new[43]|giv[44]	coref	7-24[60_44]
5-21	994-998	care	abstract[39]|abstract[41]|abstract[42]|abstract[43]|abstract[44]	giv[39]|new[41]|new[42]|new[43]|giv[44]	_	_
5-22	999-1000	,	_	_	_	_
5-23	1001-1004	are	_	_	_	_
5-24	1005-1010	being	_	_	_	_
5-25	1011-1021	considered	_	_	_	_
5-26	1022-1031	important	_	_	_	_
5-27	1032-1033	.	_	_	_	_

#Text=Frailty progresses as vulnerability to stress increases due to declining physiological reserves with aging , making one prone to unhealthy conditions .
6-1	1034-1041	Frailty	abstract	giv	ana	6-17
6-2	1042-1052	progresses	_	_	_	_
6-3	1053-1055	as	_	_	_	_
6-4	1056-1069	vulnerability	abstract[46]	new[46]	_	_
6-5	1070-1072	to	abstract[46]	new[46]	_	_
6-6	1073-1079	stress	abstract[46]|abstract	new[46]|new	_	_
6-7	1080-1089	increases	_	_	_	_
6-8	1090-1093	due	_	_	_	_
6-9	1094-1096	to	_	_	_	_
6-10	1097-1106	declining	abstract[48]	new[48]	_	_
6-11	1107-1120	physiological	abstract[48]	new[48]	_	_
6-12	1121-1129	reserves	abstract[48]	new[48]	_	_
6-13	1130-1134	with	_	_	_	_
6-14	1135-1140	aging	abstract	giv	coref	15-18
6-15	1141-1142	,	_	_	_	_
6-16	1143-1149	making	_	_	_	_
6-17	1150-1153	one	abstract	giv	ana	7-1
6-18	1154-1159	prone	_	_	_	_
6-19	1160-1162	to	_	_	_	_
6-20	1163-1172	unhealthy	abstract[51]	new[51]	_	_
6-21	1173-1183	conditions	abstract[51]	new[51]	_	_
6-22	1184-1185	.	_	_	_	_

#Text=It is a factor that increases the risk of falling , disabilities in activities of daily living , onset of the need for long-term care , and death .
7-1	1186-1188	It	abstract	giv	coref	7-3[53_0]
7-2	1189-1191	is	_	_	_	_
7-3	1192-1193	a	abstract[53]	giv[53]	coref	8-1[62_53]
7-4	1194-1200	factor	abstract[53]	giv[53]	_	_
7-5	1201-1205	that	abstract[53]	giv[53]	_	_
7-6	1206-1215	increases	abstract[53]	giv[53]	_	_
7-7	1216-1219	the	abstract[53]|abstract[54]	giv[53]|giv[54]	coref	13-19[0_54]
7-8	1220-1224	risk	abstract[53]|abstract[54]	giv[53]|giv[54]	_	_
7-9	1225-1227	of	abstract[53]|abstract[54]	giv[53]|giv[54]	_	_
7-10	1228-1235	falling	abstract[53]|abstract[54]	giv[53]|giv[54]	_	_
7-11	1236-1237	,	abstract[53]	giv[53]	_	_
7-12	1238-1250	disabilities	abstract[53]|abstract[55]	giv[53]|new[55]	_	_
7-13	1251-1253	in	abstract[53]|abstract[55]	giv[53]|new[55]	_	_
7-14	1254-1264	activities	abstract[53]|abstract[55]|event[56]	giv[53]|new[55]|giv[56]	_	_
7-15	1265-1267	of	abstract[53]|abstract[55]|event[56]	giv[53]|new[55]|giv[56]	_	_
7-16	1268-1273	daily	abstract[53]|abstract[55]|event[56]|abstract[57]	giv[53]|new[55]|giv[56]|giv[57]	coref	9-9[73_57]
7-17	1274-1280	living	abstract[53]|abstract[55]|event[56]|abstract[57]	giv[53]|new[55]|giv[56]|giv[57]	_	_
7-18	1281-1282	,	abstract[53]	giv[53]	_	_
7-19	1283-1288	onset	abstract[53]|event[58]	giv[53]|new[58]	_	_
7-20	1289-1291	of	abstract[53]|event[58]	giv[53]|new[58]	_	_
7-21	1292-1295	the	abstract[53]|event[58]|abstract[59]	giv[53]|new[58]|giv[59]	_	_
7-22	1296-1300	need	abstract[53]|event[58]|abstract[59]	giv[53]|new[58]|giv[59]	_	_
7-23	1301-1304	for	abstract[53]|event[58]|abstract[59]	giv[53]|new[58]|giv[59]	_	_
7-24	1305-1314	long-term	abstract[53]|event[58]|abstract[59]|abstract[60]	giv[53]|new[58]|giv[59]|giv[60]	_	_
7-25	1315-1319	care	abstract[53]|event[58]|abstract[59]|abstract[60]	giv[53]|new[58]|giv[59]|giv[60]	_	_
7-26	1320-1321	,	abstract[53]	giv[53]	_	_
7-27	1322-1325	and	abstract[53]	giv[53]	_	_
7-28	1326-1331	death	abstract[53]|event	giv[53]|new	_	_
7-29	1332-1333	.	_	_	_	_

#Text=Frailty as a concept includes not only physical problems , such as the representative decline in muscle strength , but also mental and physical problems , such as cognitive impairment and depression .
8-1	1334-1341	Frailty	abstract[62]	giv[62]	coref	11-1[0_62]
8-2	1342-1344	as	abstract[62]	giv[62]	_	_
8-3	1345-1346	a	abstract[62]|abstract[63]	giv[62]|new[63]	_	_
8-4	1347-1354	concept	abstract[62]|abstract[63]	giv[62]|new[63]	_	_
8-5	1355-1363	includes	_	_	_	_
8-6	1364-1367	not	_	_	_	_
8-7	1368-1372	only	abstract[64]	new[64]	_	_
8-8	1373-1381	physical	abstract[64]	new[64]	_	_
8-9	1382-1390	problems	abstract[64]	new[64]	_	_
8-10	1391-1392	,	abstract[64]	new[64]	_	_
8-11	1393-1397	such	abstract[64]	new[64]	_	_
8-12	1398-1400	as	abstract[64]	new[64]	_	_
8-13	1401-1404	the	abstract[64]|event[65]	new[64]|new[65]	ana	9-1[0_65]
8-14	1405-1419	representative	abstract[64]|event[65]	new[64]|new[65]	_	_
8-15	1420-1427	decline	abstract[64]|event[65]	new[64]|new[65]	_	_
8-16	1428-1430	in	abstract[64]|event[65]	new[64]|new[65]	_	_
8-17	1431-1437	muscle	abstract[64]|event[65]|object|abstract[67]	new[64]|new[65]|new|new[67]	coref|coref	14-17|16-30[124_67]
8-18	1438-1446	strength	abstract[64]|event[65]|abstract[67]	new[64]|new[65]|new[67]	_	_
8-19	1447-1448	,	_	_	_	_
8-20	1449-1452	but	_	_	_	_
8-21	1453-1457	also	_	_	_	_
8-22	1458-1464	mental	abstract[68]	new[68]	coref	9-4[72_68]
8-23	1465-1468	and	abstract[68]	new[68]	_	_
8-24	1469-1477	physical	abstract[68]	new[68]	_	_
8-25	1478-1486	problems	abstract[68]	new[68]	_	_
8-26	1487-1488	,	abstract[68]	new[68]	_	_
8-27	1489-1493	such	abstract[68]	new[68]	_	_
8-28	1494-1496	as	abstract[68]	new[68]	_	_
8-29	1497-1506	cognitive	abstract[68]|abstract[69]	new[68]|giv[69]	_	_
8-30	1507-1517	impairment	abstract[68]|abstract[69]	new[68]|giv[69]	_	_
8-31	1518-1521	and	abstract[68]	new[68]	_	_
8-32	1522-1532	depression	abstract[68]|abstract	new[68]|new	_	_
8-33	1533-1534	.	_	_	_	_

#Text=It also includes social problems , such as solitary living and economic distress .
9-1	1535-1537	It	event	giv	_	_
9-2	1538-1542	also	_	_	_	_
9-3	1543-1551	includes	_	_	_	_
9-4	1552-1558	social	abstract[72]	giv[72]	_	_
9-5	1559-1567	problems	abstract[72]	giv[72]	_	_
9-6	1568-1569	,	abstract[72]	giv[72]	_	_
9-7	1570-1574	such	abstract[72]	giv[72]	_	_
9-8	1575-1577	as	abstract[72]	giv[72]	_	_
9-9	1578-1586	solitary	abstract[72]|abstract[73]	giv[72]|giv[73]	coref	12-21[82_73]
9-10	1587-1593	living	abstract[72]|abstract[73]	giv[72]|giv[73]	_	_
9-11	1594-1597	and	abstract[72]	giv[72]	_	_
9-12	1598-1606	economic	abstract[72]|abstract[74]	giv[72]|new[74]	ana	10-3[0_74]
9-13	1607-1615	distress	abstract[72]|abstract[74]	giv[72]|new[74]	_	_
9-14	1616-1617	.	_	_	_	_

#Text=Accordingly , it needs to be considered comprehensively .
10-1	1618-1629	Accordingly	_	_	_	_
10-2	1630-1631	,	_	_	_	_
10-3	1632-1634	it	abstract	giv	_	_
10-4	1635-1640	needs	_	_	_	_
10-5	1641-1643	to	_	_	_	_
10-6	1644-1646	be	_	_	_	_
10-7	1647-1657	considered	_	_	_	_
10-8	1658-1673	comprehensively	_	_	_	_
10-9	1674-1675	.	_	_	_	_

#Text=Frailty is said to be reversible .
11-1	1676-1683	Frailty	abstract	giv	ana	12-3
11-2	1684-1686	is	_	_	_	_
11-3	1687-1691	said	_	_	_	_
11-4	1692-1694	to	_	_	_	_
11-5	1695-1697	be	_	_	_	_
11-6	1698-1708	reversible	_	_	_	_
11-7	1709-1710	.	_	_	_	_

#Text=Therefore , it is expected that appropriate intervention for frail older adults will lead to improvements in physical function and daily living capabilities , help reverse frailty , and prevent the onset of functional disorders .
12-1	1711-1720	Therefore	_	_	_	_
12-2	1721-1722	,	_	_	_	_
12-3	1723-1725	it	abstract	giv	coref	12-27
12-4	1726-1728	is	_	_	_	_
12-5	1729-1737	expected	_	_	_	_
12-6	1738-1742	that	_	_	_	_
12-7	1743-1754	appropriate	event[78]	new[78]	coref	19-11[148_78]
12-8	1755-1767	intervention	event[78]	new[78]	_	_
12-9	1768-1771	for	event[78]	new[78]	_	_
12-10	1772-1777	frail	event[78]|person[79]	new[78]|giv[79]	coref	19-7[146_79]
12-11	1778-1783	older	event[78]|person[79]	new[78]|giv[79]	_	_
12-12	1784-1790	adults	event[78]|person[79]	new[78]|giv[79]	_	_
12-13	1791-1795	will	_	_	_	_
12-14	1796-1800	lead	_	_	_	_
12-15	1801-1803	to	_	_	_	_
12-16	1804-1816	improvements	abstract[80]	new[80]	_	_
12-17	1817-1819	in	abstract[80]	new[80]	_	_
12-18	1820-1828	physical	abstract[80]|abstract[81]	new[80]|new[81]	coref	16-34[126_81]
12-19	1829-1837	function	abstract[80]|abstract[81]	new[80]|new[81]	_	_
12-20	1838-1841	and	abstract[80]	new[80]	_	_
12-21	1842-1847	daily	abstract[80]|abstract[82]|abstract[83]	new[80]|giv[82]|new[83]	_	_
12-22	1848-1854	living	abstract[80]|abstract[82]|abstract[83]	new[80]|giv[82]|new[83]	_	_
12-23	1855-1867	capabilities	abstract[80]|abstract[83]	new[80]|new[83]	_	_
12-24	1868-1869	,	_	_	_	_
12-25	1870-1874	help	_	_	_	_
12-26	1875-1882	reverse	_	_	_	_
12-27	1883-1890	frailty	abstract	giv	coref	13-6
12-28	1891-1892	,	_	_	_	_
12-29	1893-1896	and	_	_	_	_
12-30	1897-1904	prevent	_	_	_	_
12-31	1905-1908	the	event[85]	new[85]	_	_
12-32	1909-1914	onset	event[85]	new[85]	_	_
12-33	1915-1917	of	event[85]	new[85]	_	_
12-34	1918-1928	functional	event[85]|abstract[86]	new[85]|giv[86]	_	_
12-35	1929-1938	disorders	event[85]|abstract[86]	new[85]|giv[86]	_	_
12-36	1939-1940	.	_	_	_	_

#Text=For prevention and improvement of frailty , the key points will be active promotion of early identification of risk and desirable interventions as early measures .
13-1	1941-1944	For	_	_	_	_
13-2	1945-1955	prevention	abstract|abstract[88]	new|new[88]	coref|coref	18-12[140_0]|23-15[187_88]
13-3	1956-1959	and	abstract[88]	new[88]	_	_
13-4	1960-1971	improvement	abstract[88]|abstract[89]	new[88]|new[89]	_	_
13-5	1972-1974	of	abstract[88]|abstract[89]	new[88]|new[89]	_	_
13-6	1975-1982	frailty	abstract[88]|abstract[89]|abstract	new[88]|new[89]|giv	coref	22-13
13-7	1983-1984	,	_	_	_	_
13-8	1985-1988	the	event[91]	new[91]	coref	13-13[92_91]
13-9	1989-1992	key	event[91]	new[91]	_	_
13-10	1993-1999	points	event[91]	new[91]	_	_
13-11	2000-2004	will	_	_	_	_
13-12	2005-2007	be	_	_	_	_
13-13	2008-2014	active	event[92]	giv[92]	_	_
13-14	2015-2024	promotion	event[92]	giv[92]	_	_
13-15	2025-2027	of	event[92]	giv[92]	_	_
13-16	2028-2033	early	event[92]|abstract[93]	giv[92]|new[93]	_	_
13-17	2034-2048	identification	event[92]|abstract[93]	giv[92]|new[93]	_	_
13-18	2049-2051	of	event[92]|abstract[93]	giv[92]|new[93]	_	_
13-19	2052-2056	risk	event[92]|abstract[93]|abstract	giv[92]|new[93]|giv	_	_
13-20	2057-2060	and	event[92]	giv[92]	_	_
13-21	2061-2070	desirable	event[92]|event[95]	giv[92]|new[95]	coref	20-6[154_95]
13-22	2071-2084	interventions	event[92]|event[95]	giv[92]|new[95]	_	_
13-23	2085-2087	as	event[92]|event[95]	giv[92]|new[95]	_	_
13-24	2088-2093	early	event[92]|event[95]|abstract[96]	giv[92]|new[95]|giv[96]	coref	18-10[139_96]
13-25	2094-2102	measures	event[92]|event[95]|abstract[96]	giv[92]|new[95]|giv[96]	_	_
13-26	2103-2104	.	_	_	_	_

#Text=“ Sarcopenia ” is a coined word , where “ sarx ( sarco ) ” means muscle and “ penia ” means “ loss and reduction ” in Greek , and it was first proposed by Rosenberg in 1989 .
14-1	2105-2106	“	_	_	_	_
14-2	2107-2117	Sarcopenia	abstract	giv	coref	14-5[98_0]
14-3	2118-2119	”	_	_	_	_
14-4	2120-2122	is	_	_	_	_
14-5	2123-2124	a	abstract[98]	giv[98]	ana	14-32[0_98]
14-6	2125-2131	coined	abstract[98]	giv[98]	_	_
14-7	2132-2136	word	abstract[98]	giv[98]	_	_
14-8	2137-2138	,	abstract[98]	giv[98]	_	_
14-9	2139-2144	where	abstract[98]	giv[98]	_	_
14-10	2145-2146	“	abstract[98]	giv[98]	_	_
14-11	2147-2151	sarx	abstract[98]|abstract	giv[98]|new	appos	14-13
14-12	2152-2153	(	abstract[98]	giv[98]	_	_
14-13	2154-2159	sarco	abstract[98]|abstract	giv[98]|giv	_	_
14-14	2160-2161	)	abstract[98]	giv[98]	_	_
14-15	2162-2163	”	abstract[98]	giv[98]	_	_
14-16	2164-2169	means	abstract[98]	giv[98]	_	_
14-17	2170-2176	muscle	abstract[98]|object	giv[98]|giv	coref	15-15
14-18	2177-2180	and	abstract[98]	giv[98]	_	_
14-19	2181-2182	“	abstract[98]	giv[98]	_	_
14-20	2183-2188	penia	abstract[98]|abstract	giv[98]|new	_	_
14-21	2189-2190	”	abstract[98]	giv[98]	_	_
14-22	2191-2196	means	abstract[98]	giv[98]	_	_
14-23	2197-2198	“	abstract[98]	giv[98]	_	_
14-24	2199-2203	loss	abstract[98]|event	giv[98]|new	coref	16-33[127_0]
14-25	2204-2207	and	abstract[98]	giv[98]	_	_
14-26	2208-2217	reduction	abstract[98]|abstract	giv[98]|new	coref	16-24[120_0]
14-27	2218-2219	”	abstract[98]	giv[98]	_	_
14-28	2220-2222	in	abstract[98]	giv[98]	_	_
14-29	2223-2228	Greek	abstract[98]|abstract	giv[98]|new	_	_
14-30	2229-2230	,	abstract[98]	giv[98]	_	_
14-31	2231-2234	and	abstract[98]	giv[98]	_	_
14-32	2235-2237	it	abstract[98]|abstract	giv[98]|giv	ana	15-3
14-33	2238-2241	was	abstract[98]	giv[98]	_	_
14-34	2242-2247	first	abstract[98]	giv[98]	_	_
14-35	2248-2256	proposed	abstract[98]	giv[98]	_	_
14-36	2257-2259	by	_	_	_	_
14-37	2260-2269	Rosenberg	person	new	_	_
14-38	2270-2272	in	_	_	_	_
14-39	2273-2277	1989	time	new	_	_
14-40	2278-2279	.	_	_	_	_

#Text=Originally , it had a strong physiological nuance of decrease ( atrophy ) in muscle mass with aging .
15-1	2280-2290	Originally	_	_	_	_
15-2	2291-2292	,	_	_	_	_
15-3	2293-2295	it	abstract	giv	coref	16-6[117_0]
15-4	2296-2299	had	_	_	_	_
15-5	2300-2301	a	abstract[110]	new[110]	_	_
15-6	2302-2308	strong	abstract[110]	new[110]	_	_
15-7	2309-2322	physiological	abstract[110]	new[110]	_	_
15-8	2323-2329	nuance	abstract[110]	new[110]	_	_
15-9	2330-2332	of	abstract[110]	new[110]	_	_
15-10	2333-2341	decrease	abstract[110]|event	new[110]|new	_	_
15-11	2342-2343	(	_	_	_	_
15-12	2344-2351	atrophy	abstract	new	_	_
15-13	2352-2353	)	_	_	_	_
15-14	2354-2356	in	_	_	_	_
15-15	2357-2363	muscle	object|abstract[114]	giv|new[114]	coref|coref	16-27|16-27[122_114]
15-16	2364-2368	mass	abstract[114]	new[114]	_	_
15-17	2369-2373	with	abstract[114]	new[114]	_	_
15-18	2374-2379	aging	abstract[114]|abstract	new[114]|giv	coref	16-8
15-19	2380-2381	.	_	_	_	_

#Text=However , in addition to primary ( aging ) sarcopenia , a broader definition is taking hold , which includes as secondary sarcopenia the reduction in muscle mass and muscle strength and further muscle function loss , due to factors associated with activity , disease , and nutrition .
16-1	2382-2389	However	_	_	_	_
16-2	2390-2391	,	_	_	_	_
16-3	2392-2394	in	_	_	_	_
16-4	2395-2403	addition	_	_	_	_
16-5	2404-2406	to	_	_	_	_
16-6	2407-2414	primary	abstract[117]	giv[117]	_	_
16-7	2415-2416	(	abstract[117]	giv[117]	_	_
16-8	2417-2422	aging	abstract|abstract[117]	giv|giv[117]	_	_
16-9	2423-2424	)	abstract[117]	giv[117]	_	_
16-10	2425-2435	sarcopenia	abstract[117]	giv[117]	_	_
16-11	2436-2437	,	_	_	_	_
16-12	2438-2439	a	abstract[118]	new[118]	_	_
16-13	2440-2447	broader	abstract[118]	new[118]	_	_
16-14	2448-2458	definition	abstract[118]	new[118]	_	_
16-15	2459-2461	is	_	_	_	_
16-16	2462-2468	taking	_	_	_	_
16-17	2469-2473	hold	_	_	_	_
16-18	2474-2475	,	_	_	_	_
16-19	2476-2481	which	_	_	_	_
16-20	2482-2490	includes	_	_	_	_
16-21	2491-2493	as	_	_	_	_
16-22	2494-2503	secondary	abstract[119]	new[119]	coref	17-4[0_119]
16-23	2504-2514	sarcopenia	abstract[119]	new[119]	_	_
16-24	2515-2518	the	abstract[120]	giv[120]	_	_
16-25	2519-2528	reduction	abstract[120]	giv[120]	_	_
16-26	2529-2531	in	abstract[120]	giv[120]	_	_
16-27	2532-2538	muscle	abstract[120]|object|abstract[122]	giv[120]|giv|giv[122]	coref|coref	16-30|24-5[192_122]
16-28	2539-2543	mass	abstract[120]|abstract[122]	giv[120]|giv[122]	_	_
16-29	2544-2547	and	abstract[120]	giv[120]	_	_
16-30	2548-2554	muscle	abstract[120]|object|abstract[124]	giv[120]|giv|giv[124]	coref|coref	16-34|21-4[0_124]
16-31	2555-2563	strength	abstract[120]|abstract[124]	giv[120]|giv[124]	_	_
16-32	2564-2567	and	abstract[120]	giv[120]	_	_
16-33	2568-2575	further	abstract[120]|event[127]	giv[120]|giv[127]	_	_
16-34	2576-2582	muscle	abstract[120]|object|abstract[126]|event[127]	giv[120]|giv|giv[126]|giv[127]	coref|coref	21-27|25-28[210_126]
16-35	2583-2591	function	abstract[120]|abstract[126]|event[127]	giv[120]|giv[126]|giv[127]	_	_
16-36	2592-2596	loss	abstract[120]|event[127]	giv[120]|giv[127]	_	_
16-37	2597-2598	,	_	_	_	_
16-38	2599-2602	due	_	_	_	_
16-39	2603-2605	to	_	_	_	_
16-40	2606-2613	factors	abstract[128]	giv[128]	_	_
16-41	2614-2624	associated	abstract[128]	giv[128]	_	_
16-42	2625-2629	with	abstract[128]	giv[128]	_	_
16-43	2630-2638	activity	abstract[128]|event	giv[128]|new	_	_
16-44	2639-2640	,	abstract[128]	giv[128]	_	_
16-45	2641-2648	disease	abstract[128]|abstract	giv[128]|giv	coref	18-6[138_0]
16-46	2649-2650	,	abstract[128]	giv[128]	_	_
16-47	2651-2654	and	abstract[128]	giv[128]	_	_
16-48	2655-2664	nutrition	abstract[128]|abstract	giv[128]|new	_	_
16-49	2665-2666	.	_	_	_	_

#Text=In 2016 , sarcopenia was registered in the International Classification of Diseases ( ICD-10 ) .
17-1	2667-2669	In	_	_	_	_
17-2	2670-2674	2016	time	new	_	_
17-3	2675-2676	,	_	_	_	_
17-4	2677-2687	sarcopenia	abstract	giv	coref	18-20
17-5	2688-2691	was	_	_	_	_
17-6	2692-2702	registered	_	_	_	_
17-7	2703-2705	in	_	_	_	_
17-8	2706-2709	the	organization[134]	new[134]	_	_
17-9	2710-2723	International	organization[134]	new[134]	_	_
17-10	2724-2738	Classification	organization[134]	new[134]	_	_
17-11	2739-2741	of	organization[134]	new[134]	_	_
17-12	2742-2750	Diseases	organization[134]|abstract	new[134]|new	_	_
17-13	2751-2752	(	_	_	_	_
17-14	2753-2759	ICD-10	abstract	new	ana	18-1
17-15	2760-2761	)	_	_	_	_
17-16	2762-2763	.	_	_	_	_

#Text=It is now considered as a disease , and measures for the prevention , treatment , and improvement of sarcopenia are urgently needed in the future .
18-1	2764-2766	It	abstract	giv	_	_
18-2	2767-2769	is	_	_	_	_
18-3	2770-2773	now	_	_	_	_
18-4	2774-2784	considered	_	_	_	_
18-5	2785-2787	as	_	_	_	_
18-6	2788-2789	a	abstract[138]	giv[138]	_	_
18-7	2790-2797	disease	abstract[138]	giv[138]	_	_
18-8	2798-2799	,	_	_	_	_
18-9	2800-2803	and	_	_	_	_
18-10	2804-2812	measures	abstract[139]	giv[139]	coref	23-13[185_139]
18-11	2813-2816	for	abstract[139]	giv[139]	_	_
18-12	2817-2820	the	abstract[139]|abstract[140]	giv[139]|giv[140]	coref	23-15[0_140]
18-13	2821-2831	prevention	abstract[139]|abstract[140]	giv[139]|giv[140]	_	_
18-14	2832-2833	,	abstract[139]	giv[139]	_	_
18-15	2834-2843	treatment	abstract[139]|abstract	giv[139]|giv	_	_
18-16	2844-2845	,	abstract[139]	giv[139]	_	_
18-17	2846-2849	and	abstract[139]	giv[139]	_	_
18-18	2850-2861	improvement	abstract[139]|abstract[142]	giv[139]|new[142]	coref	23-17[188_142]
18-19	2862-2864	of	abstract[139]|abstract[142]	giv[139]|new[142]	_	_
18-20	2865-2875	sarcopenia	abstract[139]|abstract[142]|abstract	giv[139]|new[142]|giv	ana	19-1
18-21	2876-2879	are	_	_	_	_
18-22	2880-2888	urgently	_	_	_	_
18-23	2889-2895	needed	_	_	_	_
18-24	2896-2898	in	_	_	_	_
18-25	2899-2902	the	time[144]	new[144]	_	_
18-26	2903-2909	future	time[144]	new[144]	_	_
18-27	2910-2911	.	_	_	_	_

#Text=It has been reported that in frail older adults , exercise intervention is effective in improving physical functions , including gait speed .
19-1	2912-2914	It	abstract	giv	coref	23-19
19-2	2915-2918	has	_	_	_	_
19-3	2919-2923	been	_	_	_	_
19-4	2924-2932	reported	_	_	_	_
19-5	2933-2937	that	_	_	_	_
19-6	2938-2940	in	_	_	_	_
19-7	2941-2946	frail	person[146]	giv[146]	coref	21-30[167_146]
19-8	2947-2952	older	person[146]	giv[146]	_	_
19-9	2953-2959	adults	person[146]	giv[146]	_	_
19-10	2960-2961	,	_	_	_	_
19-11	2962-2970	exercise	event|event[148]	new|giv[148]	coref|coref	20-6[153_148]|21-8
19-12	2971-2983	intervention	event[148]	giv[148]	_	_
19-13	2984-2986	is	_	_	_	_
19-14	2987-2996	effective	_	_	_	_
19-15	2997-2999	in	_	_	_	_
19-16	3000-3009	improving	_	_	_	_
19-17	3010-3018	physical	abstract[149]	new[149]	_	_
19-18	3019-3028	functions	abstract[149]	new[149]	_	_
19-19	3029-3030	,	abstract[149]	new[149]	_	_
19-20	3031-3040	including	abstract[149]	new[149]	_	_
19-21	3041-3045	gait	abstract[149]|abstract|abstract[151]	new[149]|new|new[151]	_	_
19-22	3046-3051	speed	abstract[149]|abstract[151]	new[149]|new[151]	_	_
19-23	3052-3053	.	_	_	_	_

#Text=However , the effects of the recommended specific event , frequency , and time have not been clarified .
20-1	3054-3061	However	_	_	_	_
20-2	3062-3063	,	_	_	_	_
20-3	3064-3067	the	abstract[152]	new[152]	_	_
20-4	3068-3075	effects	abstract[152]	new[152]	_	_
20-5	3076-3078	of	abstract[152]	new[152]	_	_
20-6	3079-3082	the	abstract[152]|event[153]|event[154]	new[152]|giv[153]|giv[154]	coref	22-6[169_154]
20-7	3083-3094	recommended	abstract[152]|event[153]|event[154]	new[152]|giv[153]|giv[154]	_	_
20-8	3095-3103	specific	abstract[152]|event[153]|event[154]	new[152]|giv[153]|giv[154]	_	_
20-9	3104-3109	event	abstract[152]|event[153]|event[154]	new[152]|giv[153]|giv[154]	_	_
20-10	3110-3111	,	abstract[152]|event[154]	new[152]|giv[154]	_	_
20-11	3112-3121	frequency	abstract[152]|event[154]|abstract	new[152]|giv[154]|new	_	_
20-12	3122-3123	,	abstract[152]|event[154]	new[152]|giv[154]	_	_
20-13	3124-3127	and	abstract[152]|event[154]	new[152]|giv[154]	_	_
20-14	3128-3132	time	abstract[152]|event[154]|time	new[152]|giv[154]|new	_	_
20-15	3133-3137	have	_	_	_	_
20-16	3138-3141	not	_	_	_	_
20-17	3142-3146	been	_	_	_	_
20-18	3147-3156	clarified	_	_	_	_
20-19	3157-3158	.	_	_	_	_

#Text=In addition to strength training , multifaceted exercise programs that incorporate flexible exercise , balance exercise , and aerobic exercise have also been reported to improve muscle strength in frail older adults .
21-1	3159-3161	In	_	_	_	_
21-2	3162-3170	addition	_	_	_	_
21-3	3171-3173	to	_	_	_	_
21-4	3174-3182	strength	abstract|abstract[158]	giv|new[158]	coref|coref	21-27[166_0]|23-1[182_158]
21-5	3183-3191	training	abstract[158]	new[158]	_	_
21-6	3192-3193	,	_	_	_	_
21-7	3194-3206	multifaceted	abstract[160]	new[160]	_	_
21-8	3207-3215	exercise	event|abstract[160]	giv|new[160]	coref	21-12[161_0]
21-9	3216-3224	programs	abstract[160]	new[160]	_	_
21-10	3225-3229	that	abstract[160]	new[160]	_	_
21-11	3230-3241	incorporate	abstract[160]	new[160]	_	_
21-12	3242-3250	flexible	abstract[160]|event[161]	new[160]|giv[161]	coref	21-15[163_161]
21-13	3251-3259	exercise	abstract[160]|event[161]	new[160]|giv[161]	_	_
21-14	3260-3261	,	abstract[160]	new[160]	_	_
21-15	3262-3269	balance	abstract[160]|abstract|event[163]	new[160]|new|giv[163]	coref	21-19[164_163]
21-16	3270-3278	exercise	abstract[160]|event[163]	new[160]|giv[163]	_	_
21-17	3279-3280	,	abstract[160]	new[160]	_	_
21-18	3281-3284	and	abstract[160]	new[160]	_	_
21-19	3285-3292	aerobic	abstract[160]|event[164]	new[160]|giv[164]	coref	25-7[0_164]
21-20	3293-3301	exercise	abstract[160]|event[164]	new[160]|giv[164]	_	_
21-21	3302-3306	have	_	_	_	_
21-22	3307-3311	also	_	_	_	_
21-23	3312-3316	been	_	_	_	_
21-24	3317-3325	reported	_	_	_	_
21-25	3326-3328	to	_	_	_	_
21-26	3329-3336	improve	_	_	_	_
21-27	3337-3343	muscle	object|abstract[166]	giv|giv[166]	ana|coref	22-1[0_166]|22-18
21-28	3344-3352	strength	abstract[166]	giv[166]	_	_
21-29	3353-3355	in	_	_	_	_
21-30	3356-3361	frail	person[167]	giv[167]	coref	24-12[195_167]
21-31	3362-3367	older	person[167]	giv[167]	_	_
21-32	3368-3374	adults	person[167]	giv[167]	_	_
21-33	3375-3376	.	_	_	_	_

#Text=It has been suggested that interventions focused on the physical elements behind frailty ( weight loss , muscle weakness , exhaustion , slowness , low physical activity ) are effective , and comprehensive interventions incorporating as many of the elements as possible are desirable .
22-1	3377-3379	It	abstract	giv	coref	24-9[194_0]
22-2	3380-3383	has	_	_	_	_
22-3	3384-3388	been	_	_	_	_
22-4	3389-3398	suggested	_	_	_	_
22-5	3399-3403	that	_	_	_	_
22-6	3404-3417	interventions	event[169]	giv[169]	appos	22-15[172_169]
22-7	3418-3425	focused	event[169]	giv[169]	_	_
22-8	3426-3428	on	event[169]	giv[169]	_	_
22-9	3429-3432	the	event[169]|abstract[170]	giv[169]|new[170]	coref	22-39[180_170]
22-10	3433-3441	physical	event[169]|abstract[170]	giv[169]|new[170]	_	_
22-11	3442-3450	elements	event[169]|abstract[170]	giv[169]|new[170]	_	_
22-12	3451-3457	behind	event[169]|abstract[170]	giv[169]|new[170]	_	_
22-13	3458-3465	frailty	event[169]|abstract[170]|abstract	giv[169]|new[170]|giv	_	_
22-14	3466-3467	(	_	_	_	_
22-15	3468-3474	weight	event[172]|event[173]	giv[172]|giv[173]	appos|appos	22-15[173_172]|22-21[0_173]
22-16	3475-3479	loss	event[172]|event[173]	giv[172]|giv[173]	_	_
22-17	3480-3481	,	event[173]	giv[173]	_	_
22-18	3482-3488	muscle	event[173]|object|abstract[175]	giv[173]|giv|new[175]	coref	24-6
22-19	3489-3497	weakness	event[173]|abstract[175]	giv[173]|new[175]	_	_
22-20	3498-3499	,	event[173]	giv[173]	_	_
22-21	3500-3510	exhaustion	event[173]|event	giv[173]|giv	appos	22-23
22-22	3511-3512	,	event[173]	giv[173]	_	_
22-23	3513-3521	slowness	event[173]|event	giv[173]|giv	appos	22-25[178_0]
22-24	3522-3523	,	event[173]	giv[173]	_	_
22-25	3524-3527	low	event[173]|event[178]	giv[173]|giv[178]	coref	22-33[179_178]
22-26	3528-3536	physical	event[173]|event[178]	giv[173]|giv[178]	_	_
22-27	3537-3545	activity	event[173]|event[178]	giv[173]|giv[178]	_	_
22-28	3546-3547	)	_	_	_	_
22-29	3548-3551	are	_	_	_	_
22-30	3552-3561	effective	_	_	_	_
22-31	3562-3563	,	_	_	_	_
22-32	3564-3567	and	_	_	_	_
22-33	3568-3581	comprehensive	event[179]	giv[179]	coref	23-4[184_179]
22-34	3582-3595	interventions	event[179]	giv[179]	_	_
22-35	3596-3609	incorporating	event[179]	giv[179]	_	_
22-36	3610-3612	as	event[179]	giv[179]	_	_
22-37	3613-3617	many	event[179]	giv[179]	_	_
22-38	3618-3620	of	_	_	_	_
22-39	3621-3624	the	abstract[180]	giv[180]	_	_
22-40	3625-3633	elements	abstract[180]	giv[180]	_	_
22-41	3634-3636	as	abstract[180]	giv[180]	_	_
22-42	3637-3645	possible	abstract[180]	giv[180]	_	_
22-43	3646-3649	are	_	_	_	_
22-44	3650-3659	desirable	_	_	_	_
22-45	3660-3661	.	_	_	_	_

#Text=Resistance training and nutritional ( protein ) interventions are often selected as measures for prevention and improvement of sarcopenia .
23-1	3662-3672	Resistance	organization|abstract[182]	new|giv[182]	_	_
23-2	3673-3681	training	abstract[182]	giv[182]	_	_
23-3	3682-3685	and	_	_	_	_
23-4	3686-3697	nutritional	event[184]	giv[184]	coref	26-10[212_184]
23-5	3698-3699	(	event[184]	giv[184]	_	_
23-6	3700-3707	protein	substance|event[184]	new|giv[184]	coref	27-10[216_0]
23-7	3708-3709	)	event[184]	giv[184]	_	_
23-8	3710-3723	interventions	event[184]	giv[184]	_	_
23-9	3724-3727	are	_	_	_	_
23-10	3728-3733	often	_	_	_	_
23-11	3734-3742	selected	_	_	_	_
23-12	3743-3745	as	_	_	_	_
23-13	3746-3754	measures	abstract[185]	giv[185]	_	_
23-14	3755-3758	for	abstract[185]	giv[185]	_	_
23-15	3759-3769	prevention	abstract[185]|abstract|abstract[187]	giv[185]|giv|giv[187]	_	_
23-16	3770-3773	and	abstract[185]|abstract[187]	giv[185]|giv[187]	_	_
23-17	3774-3785	improvement	abstract[185]|abstract[187]|abstract[188]	giv[185]|giv[187]|giv[188]	_	_
23-18	3786-3788	of	abstract[185]|abstract[187]|abstract[188]	giv[185]|giv[187]|giv[188]	_	_
23-19	3789-3799	sarcopenia	abstract[185]|abstract[187]|abstract[188]|abstract	giv[185]|giv[187]|giv[188]|giv	coref	28-19
23-20	3800-3801	.	_	_	_	_

#Text=In a report on increased muscle mass and muscle strength in older adults , a high load of 70 – 80 % of 1 repetition maximum ( RM ) was used .
24-1	3802-3804	In	_	_	_	_
24-2	3805-3806	a	abstract[190]	new[190]	_	_
24-3	3807-3813	report	abstract[190]	new[190]	_	_
24-4	3814-3816	on	abstract[190]	new[190]	_	_
24-5	3817-3826	increased	abstract[190]|abstract[192]	new[190]|giv[192]	coref	27-24[222_192]
24-6	3827-3833	muscle	abstract[190]|object|abstract[192]	new[190]|giv|giv[192]	coref	24-9
24-7	3834-3838	mass	abstract[190]|abstract[192]	new[190]|giv[192]	_	_
24-8	3839-3842	and	abstract[190]	new[190]	_	_
24-9	3843-3849	muscle	abstract[190]|object|abstract[194]	new[190]|giv|giv[194]	coref|coref	25-28|27-28[224_194]
24-10	3850-3858	strength	abstract[190]|abstract[194]	new[190]|giv[194]	_	_
24-11	3859-3861	in	abstract[190]|abstract[194]	new[190]|giv[194]	_	_
24-12	3862-3867	older	abstract[190]|abstract[194]|person[195]	new[190]|giv[194]|giv[195]	coref	25-4[201_195]
24-13	3868-3874	adults	abstract[190]|abstract[194]|person[195]	new[190]|giv[194]|giv[195]	_	_
24-14	3875-3876	,	_	_	_	_
24-15	3877-3878	a	abstract[196]	new[196]	_	_
24-16	3879-3883	high	abstract[196]	new[196]	_	_
24-17	3884-3888	load	abstract[196]	new[196]	_	_
24-18	3889-3891	of	abstract[196]	new[196]	_	_
24-19	3892-3894	70	abstract[196]|abstract[197]	new[196]|new[197]	_	_
24-20	3895-3896	–	abstract[196]|abstract[197]	new[196]|new[197]	_	_
24-21	3897-3899	80	abstract[196]|abstract[197]	new[196]|new[197]	_	_
24-22	3900-3901	%	abstract[196]|abstract[197]	new[196]|new[197]	_	_
24-23	3902-3904	of	abstract[196]|abstract[197]	new[196]|new[197]	_	_
24-24	3905-3906	1	abstract[196]|abstract[197]|event[198]|abstract[199]	new[196]|new[197]|new[198]|new[199]	appos	24-28[0_199]
24-25	3907-3917	repetition	abstract[196]|abstract[197]|event[198]|abstract[199]	new[196]|new[197]|new[198]|new[199]	_	_
24-26	3918-3925	maximum	abstract[196]|abstract[197]|abstract[199]	new[196]|new[197]|new[199]	_	_
24-27	3926-3927	(	_	_	_	_
24-28	3928-3930	RM	abstract	giv	ana	25-10
24-29	3931-3932	)	_	_	_	_
24-30	3933-3936	was	_	_	_	_
24-31	3937-3941	used	_	_	_	_
24-32	3942-3943	.	_	_	_	_

#Text=However , for older adults without exercise habits , it was reported that even with a load of 40 – 50 % of 1 RM improvement in muscle function can be expected .
25-1	3944-3951	However	_	_	_	_
25-2	3952-3953	,	_	_	_	_
25-3	3954-3957	for	_	_	_	_
25-4	3958-3963	older	person[201]	giv[201]	_	_
25-5	3964-3970	adults	person[201]	giv[201]	_	_
25-6	3971-3978	without	person[201]	giv[201]	_	_
25-7	3979-3987	exercise	person[201]|event|abstract[203]	giv[201]|giv|new[203]	coref	28-5
25-8	3988-3994	habits	person[201]|abstract[203]	giv[201]|new[203]	_	_
25-9	3995-3996	,	_	_	_	_
25-10	3997-3999	it	abstract	giv	coref	25-24[207_0]
25-11	4000-4003	was	_	_	_	_
25-12	4004-4012	reported	_	_	_	_
25-13	4013-4017	that	_	_	_	_
25-14	4018-4022	even	abstract[205]	new[205]	coref	26-3[211_205]
25-15	4023-4027	with	abstract[205]	new[205]	_	_
25-16	4028-4029	a	abstract[205]	new[205]	_	_
25-17	4030-4034	load	abstract[205]	new[205]	_	_
25-18	4035-4037	of	abstract[205]	new[205]	_	_
25-19	4038-4040	40	abstract[205]|abstract[206]	new[205]|new[206]	_	_
25-20	4041-4042	–	abstract[205]|abstract[206]	new[205]|new[206]	_	_
25-21	4043-4045	50	abstract[205]|abstract[206]	new[205]|new[206]	_	_
25-22	4046-4047	%	abstract[205]|abstract[206]	new[205]|new[206]	_	_
25-23	4048-4050	of	abstract[205]|abstract[206]	new[205]|new[206]	_	_
25-24	4051-4052	1	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|giv[207]	_	_
25-25	4053-4055	RM	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|giv[207]	_	_
25-26	4056-4067	improvement	abstract[208]	new[208]	_	_
25-27	4068-4070	in	abstract[208]	new[208]	_	_
25-28	4071-4077	muscle	abstract[208]|object|abstract[210]	new[208]|giv|giv[210]	coref	27-10
25-29	4078-4086	function	abstract[208]|abstract[210]	new[208]|giv[210]	_	_
25-30	4087-4090	can	_	_	_	_
25-31	4091-4093	be	_	_	_	_
25-32	4094-4102	expected	_	_	_	_
25-33	4103-4104	.	_	_	_	_

#Text=When setting a low load cannot be avoided , long-term and high frequency interventions may be necessary .
26-1	4105-4109	When	_	_	_	_
26-2	4110-4117	setting	_	_	_	_
26-3	4118-4119	a	abstract[211]	giv[211]	_	_
26-4	4120-4123	low	abstract[211]	giv[211]	_	_
26-5	4124-4128	load	abstract[211]	giv[211]	_	_
26-6	4129-4135	cannot	_	_	_	_
26-7	4136-4138	be	_	_	_	_
26-8	4139-4146	avoided	_	_	_	_
26-9	4147-4148	,	_	_	_	_
26-10	4149-4158	long-term	event[212]	giv[212]	coref	27-3[213_212]
26-11	4159-4162	and	event[212]	giv[212]	_	_
26-12	4163-4167	high	event[212]	giv[212]	_	_
26-13	4168-4177	frequency	event[212]	giv[212]	_	_
26-14	4178-4191	interventions	event[212]	giv[212]	_	_
26-15	4192-4195	may	_	_	_	_
26-16	4196-4198	be	_	_	_	_
26-17	4199-4208	necessary	_	_	_	_
26-18	4209-4210	.	_	_	_	_

#Text=Moreover , nutritional interventions for the purpose of promoting muscle protein synthesis ( such as amino acid intake ) are effective in increasing muscle mass and improving muscle strength .
27-1	4211-4219	Moreover	_	_	_	_
27-2	4220-4221	,	_	_	_	_
27-3	4222-4233	nutritional	event[213]	giv[213]	coref	28-4[226_213]
27-4	4234-4247	interventions	event[213]	giv[213]	_	_
27-5	4248-4251	for	event[213]	giv[213]	_	_
27-6	4252-4255	the	event[213]|abstract[214]	giv[213]|new[214]	_	_
27-7	4256-4263	purpose	event[213]|abstract[214]	giv[213]|new[214]	_	_
27-8	4264-4266	of	event[213]|abstract[214]	giv[213]|new[214]	_	_
27-9	4267-4276	promoting	event[213]|abstract[214]	giv[213]|new[214]	_	_
27-10	4277-4283	muscle	event[213]|abstract[214]|object|substance[216]|abstract[217]	giv[213]|new[214]|giv|giv[216]|new[217]	coref	27-24
27-11	4284-4291	protein	event[213]|abstract[214]|substance[216]|abstract[217]	giv[213]|new[214]|giv[216]|new[217]	_	_
27-12	4292-4301	synthesis	event[213]|abstract[214]|abstract[217]	giv[213]|new[214]|new[217]	_	_
27-13	4302-4303	(	event[213]|abstract[214]|abstract[217]	giv[213]|new[214]|new[217]	_	_
27-14	4304-4308	such	event[213]|abstract[214]|abstract[217]	giv[213]|new[214]|new[217]	_	_
27-15	4309-4311	as	event[213]|abstract[214]|abstract[217]	giv[213]|new[214]|new[217]	_	_
27-16	4312-4317	amino	event[213]|abstract[214]|abstract[217]|object|substance[219]|event[220]	giv[213]|new[214]|new[217]|new|new[219]|new[220]	_	_
27-17	4318-4322	acid	event[213]|abstract[214]|abstract[217]|substance[219]|event[220]	giv[213]|new[214]|new[217]|new[219]|new[220]	_	_
27-18	4323-4329	intake	event[213]|abstract[214]|abstract[217]|event[220]	giv[213]|new[214]|new[217]|new[220]	_	_
27-19	4330-4331	)	event[213]|abstract[214]|abstract[217]	giv[213]|new[214]|new[217]	_	_
27-20	4332-4335	are	_	_	_	_
27-21	4336-4345	effective	_	_	_	_
27-22	4346-4348	in	_	_	_	_
27-23	4349-4359	increasing	_	_	_	_
27-24	4360-4366	muscle	object|abstract[222]	giv|giv[222]	coref	27-28
27-25	4367-4371	mass	abstract[222]	giv[222]	_	_
27-26	4372-4375	and	_	_	_	_
27-27	4376-4385	improving	_	_	_	_
27-28	4386-4392	muscle	object|abstract[224]	giv|giv[224]	_	_
27-29	4393-4401	strength	abstract[224]	giv[224]	_	_
27-30	4402-4403	.	_	_	_	_

#Text=Accordingly , not only exercise interventions but also nutritional interventions undertaken concurrently are expected to be effective against sarcopenia .
28-1	4404-4415	Accordingly	_	_	_	_
28-2	4416-4417	,	_	_	_	_
28-3	4418-4421	not	_	_	_	_
28-4	4422-4426	only	event[226]|event[227]	giv[226]|giv[227]	coref|coref	28-4[227_226]|28-9[228_227]
28-5	4427-4435	exercise	event|event[226]|event[227]	giv|giv[226]|giv[227]	_	_
28-6	4436-4449	interventions	event[226]|event[227]	giv[226]|giv[227]	_	_
28-7	4450-4453	but	event[227]	giv[227]	_	_
28-8	4454-4458	also	event[227]	giv[227]	_	_
28-9	4459-4470	nutritional	event[227]|event[228]	giv[227]|giv[228]	_	_
28-10	4471-4484	interventions	event[227]|event[228]	giv[227]|giv[228]	_	_
28-11	4485-4495	undertaken	event[227]|event[228]	giv[227]|giv[228]	_	_
28-12	4496-4508	concurrently	event[227]|event[228]	giv[227]|giv[228]	_	_
28-13	4509-4512	are	_	_	_	_
28-14	4513-4521	expected	_	_	_	_
28-15	4522-4524	to	_	_	_	_
28-16	4525-4527	be	_	_	_	_
28-17	4528-4537	effective	_	_	_	_
28-18	4538-4545	against	_	_	_	_
28-19	4546-4556	sarcopenia	abstract	giv	_	_
28-20	4557-4558	.	_	_	_	_
